Metabolism News and Research

Latest Metabolism News and Research

Boehringer Ingelheim to present linagliptin Phase III data at 46th EASD

New Phase III data found that investigational linagliptin therapy resulted in significant reductions in blood sugar as measured by hemoglobin A1c (HbA1c) when compared to placebo, both when added to sulfonylurea (SU) in inadequately controlled type 2 diabetes (T2D) patients, and when administered as monotherapy in T2D patients for whom metformin is inappropriate.

22 Sep 2010

NIDA awards GeneGo SBIR grant to develop integrated systems biology platform for nicotine addiction research

GeneGo, Inc., the leading systems biology company, today announced that it has been awarded a grant from the National Institute on Drug Abuse to develop an integrated systems biology platform for research into the causes and treatment of tobacco dependence, nicotine addiction, smoking cessation and tobacco/nicotine withdrawal.

22 Sep 2010

Researchers receive $634,000 grant to study environmental factors, MS progression

A $634,000 grant from the Department of Defense is allowing researchers at the University at Buffalo to investigate a trio of environmental factors and their influence on the progression of multiple sclerosis.

22 Sep 2010

Dr. Shlomo Melmed awarded 9th Endocrine Regulation Prize of the Fondation Ipsen

The international jury under the presidency of Professor Iain Robinson (National Institute for Medical Research, London, UK) awarded today the 9th Endocrine Regulation Prize of the Fondation Ipsen (20.000€) to Dr. Shlomo Melmed (Cedars-Sinai Medical Center, Los Angeles, USA) during the annual congress of the ENEA (European NeuroEndocrine Association) in Liège (Belgium), for his translational approach to endocrinology. Shlomo Melmed is an internationally recognized endocrinologist and an authority on pituitary medicine.

22 Sep 2010

Novartis' SOM230 reduces cortisol levels in Cushing's disease patients

Novartis Pharmaceuticals Corporation announced today that the results of a Phase III study of SOM230 (pasireotide) showed a reduction in cortisol levels in patients with Cushing's disease, a condition in which a benign (non-cancerous) pituitary tumor causes the adrenal glands to produce excess cortisol and can be fatal. Results will be presented at the 14th Congress of the European Neuroendocrine Association (ENEA).

22 Sep 2010

Brain wolfs energy even to stop thinking

Ever wonder why it's such an effort to forget about work while on vacation or to silence that annoying song that's playing over and over in your head?

21 Sep 2010

Public health at risk as Vitamin D evidence mounts

A group of prevention-focused healthcare organizations has expressed deep concern over recently-proposed restrictions to OHIP coverage of Vitamin D testing in the province. The proposed new legislation will delist OHIP insured Vitamin D testing for most Ontarians. Exceptions will be made for those with osteoporosis, malabsorption syndromes, and individuals taking medications that interfere with vitamin D absorption or metabolism.

21 Sep 2010

Biomarkers may help predict children at high risk of developing type 2 diabetes

Children who have a high risk of developing type 2 diabetes might be identified earlier by way of tell-tale genetic indicators known as biomarkers. Some of those new biomarkers might be pinpointed in research led by Nancy F. Butte and funded by the U.S. Department of Agriculture (USDA) and the U.S. Department of Health and Human Service's National Institutes of Health.

20 Sep 2010

Seven abstracts on Lantheus' PET imaging candidates to be presented at ASNC2010

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced that seven abstracts related to two of the company's cardiac Positron Emission Tomography (PET) imaging candidates will be presented at ASNC2010, the 15th Annual Scientific Session of the American Society of Nuclear Cardiology, being held September 23-26, 2010 in Philadelphia.

20 Sep 2010

Myrexis releases MPC-9528 cancer metabolism inhibitor preclinical study results

Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced key findings from preclinical studies of the Company's novel cancer metabolism inhibitor (CMI), MPC-9528, at the Cancer and Metabolism Pathways to the Future Symposium in Edinburgh, Scotland.

20 Sep 2010

Lisofylline drug effective for Type 2 diabetes

Australian scientists, in association with US pharmaceutical company DiaKine Therapeutics, have shown that a drug candidate, Lisofylline, could be useful in treating Type 2 diabetes.

20 Sep 2010

FluimediX receives fund for NanoCycler development

FluimediX, a point-of-care diagnostic company, announced today that it has received funding for the continued development of the NanoCycler, a diagnostic platform for the measurement of relevant genetic mutations in patients. The proceeds of this financing round will be dedicated to developing a diagnostic test for Warfarin™ metabolism.

20 Sep 2010

Adenovirus exposure may cause obesity in children: Study

The emerging idea that obesity may have an infectious origin gets new support in a cross-sectional study by University of California, San Diego School of Medicine researchers who found that children exposed to a particular strain of adenovirus were significantly more likely to be obese.

20 Sep 2010

Improper biological clocks tend to develop diabetes, obesity: Research

Biologists have found that a key protein that regulates the biological clocks of mammals also regulates glucose production in the liver and that altering the levels of this protein can improve the health of diabetic mice.

20 Sep 2010

PNNL, 59th Medical Wing collaborate to improve drug tests for illicit usage

A new collaboration between the Department of Energy's Pacific Northwest National Laboratory and the Air Force's 59th Medical Wing hopes to improve on drug tests for illicit drug use and abuse. Not only are the researchers looking for a better indicator of current or past use, but they'd like to be able to identify people prone to abusing drugs in the first place.

18 Sep 2010

Study examines effects of AEDs on nicotine metabolite levels in smokers

UMDNJ-Robert Wood Johnson Medical School researchers have determined that carbamazepine and oxycarbamazepine, medications commonly used to treat neurologic and psychiatric conditions, increase nicotine metabolism in smokers. As nicotine metabolism increases, cravings for nicotine return more quickly which could lead to more frequent cigarette consumption among individuals who also take these medications.

18 Sep 2010

Arena, Eisai provide update on lorcaserin NDA

Arena Pharmaceuticals, Inc. and Eisai Inc. announced today that the US Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee voted 9 to 5 that the available data do not adequately demonstrate that the potential benefits of lorcaserin outweigh the potential risks, when used long-term in a population of overweight and obese individuals to allow marketing approval.

17 Sep 2010

Researchers find bariatric surgery reduces cardiovascular disease risk

Significant weight loss not only improves daily life of morbidly obese woman but also decreases the risk for cardiovascular disease (CVD). However, many people can not lose weight or can not maintain weight loss without help. Bariatric surgery is emerging as a valuable procedure to help morbidly obese individuals lose weight, as studies have shown; it can improve many health profiles and lower mortality. Now, researchers have found another positive impact of significant weight loss after bariatric surgery, it can significantly improve the lipoprotein profiles of women within a year following surgery.

17 Sep 2010

Myrexis to present poster on cancer metabolism inhibitor program

Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced it will present a poster at the Cancer and Metabolism: Pathways to the Future meeting in Edinburgh, Scotland, as well as two additional posters at the 22nd European Organisation for Research and Treatment of Cancer (EORTC), National Cancer Institute (NCI) and American Association for Cancer Research (AACR) Symposium on "Molecular Targets and Cancer Therapeutics" November 16-19, 2010, in Berlin, Germany.

17 Sep 2010

Scientists discover simple molecular test to block GOAT enzyme

Scientists at The Scripps Research Institute have designed a new molecular test that will allow researchers to look for potential drugs targeting a human metabolic enzyme believed to stimulate the appetite and play a role in diabetes.

17 Sep 2010